Slingshot members are tracking this event:
FDA Rolling Submission of Olaratumab Expected to be Complete By End of H1 of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
May 04, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Olaratumab, Sarcoma, Fda Rolling Submission, Nda Filing